Real-world costs of chronic lymphocytic leukaemia in the Netherlands

K. M. Holtzer-Goor; C. A. M. Bouwmans-Frijters; M. R. Schaafsma; O. de Weerdt; P. Joosten; E. F. M. Posthuma; S. Wittebol; P. C. Huijgens; E. J. M. Mattijssen; G. Vreugdenhil; H. Visser; W. G. Peters; Z. Erjavec; P. W. Wijermans; S. M. G. J. Daenen; K. G. van der Hem; M. H. J. van Oers; C. A. Uyl-de Groot; O. de Weerdtc; E.J.M. Matthssen

doi:https://doi.org/10.1016/j.leukres.2013.10.029

Real-world costs of chronic lymphocytic leukaemia in the Netherlands

K. M. Holtzer-Goor, C. A. M. Bouwmans-Frijters, M. R. Schaafsma, O. de Weerdt, P. Joosten, E. F. M. Posthuma, S. Wittebol, P. C. Huijgens, E. J. M. Mattijssen, G. Vreugdenhil, H. Visser, W. G. Peters, Z. Erjavec, P. W. Wijermans, S. M. G. J. Daenen, K. G. van der Hem, M. H. J. van Oers, C. A. Uyl-de Groot, O. de Weerdtc, E.J.M. Matthssen

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received ≥1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were €41,417 (€539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy

Original language	English
Pages (from-to)	84-90
Journal	Leukemia research
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.leukres.2013.10.029
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/j.leukres.2013.10.029

Cite this

Holtzer-Goor, K. M., Bouwmans-Frijters, C. A. M., Schaafsma, M. R., de Weerdt, O., Joosten, P., Posthuma, E. F. M., Wittebol, S., Huijgens, P. C., Mattijssen, E. J. M., Vreugdenhil, G., Visser, H., Peters, W. G., Erjavec, Z., Wijermans, P. W., Daenen, S. M. G. J., van der Hem, K. G., van Oers, M. H. J., Groot, C. A. U., de Weerdtc, O., & Matthssen, E. J. M. (2014). Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia research, 38(1), 84-90. https://doi.org/10.1016/j.leukres.2013.10.029

@article{d5f24bbea0fb4918802fcf4580c983b4,

title = "Real-world costs of chronic lymphocytic leukaemia in the Netherlands",

abstract = "We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received ≥1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were €41,417 (€539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy",

author = "Holtzer-Goor, {K. M.} and Bouwmans-Frijters, {C. A. M.} and Schaafsma, {M. R.} and {de Weerdt}, O. and P. Joosten and Posthuma, {E. F. M.} and S. Wittebol and Huijgens, {P. C.} and Mattijssen, {E. J. M.} and G. Vreugdenhil and H. Visser and Peters, {W. G.} and Z. Erjavec and Wijermans, {P. W.} and Daenen, {S. M. G. J.} and {van der Hem}, {K. G.} and {van Oers}, {M. H. J.} and Groot, {C. A. Uyl-de} and {de Weerdtc}, O. and E.J.M. Matthssen",

year = "2014",

doi = "https://doi.org/10.1016/j.leukres.2013.10.029",

language = "English",

volume = "38",

pages = "84--90",

journal = "Leukemia research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "1",

}

Holtzer-Goor, KM, Bouwmans-Frijters, CAM, Schaafsma, MR, de Weerdt, O, Joosten, P, Posthuma, EFM, Wittebol, S, Huijgens, PC, Mattijssen, EJM, Vreugdenhil, G, Visser, H, Peters, WG, Erjavec, Z, Wijermans, PW, Daenen, SMGJ, van der Hem, KG, van Oers, MHJ, Groot, CAU, de Weerdtc, O & Matthssen, EJM 2014, 'Real-world costs of chronic lymphocytic leukaemia in the Netherlands', Leukemia research, vol. 38, no. 1, pp. 84-90. https://doi.org/10.1016/j.leukres.2013.10.029

TY - JOUR

T1 - Real-world costs of chronic lymphocytic leukaemia in the Netherlands

AU - Holtzer-Goor, K. M.

AU - Bouwmans-Frijters, C. A. M.

AU - Schaafsma, M. R.

AU - de Weerdt, O.

AU - Joosten, P.

AU - Posthuma, E. F. M.

AU - Wittebol, S.

AU - Huijgens, P. C.

AU - Mattijssen, E. J. M.

AU - Vreugdenhil, G.

AU - Visser, H.

AU - Peters, W. G.

AU - Erjavec, Z.

AU - Wijermans, P. W.

AU - Daenen, S. M. G. J.

AU - van der Hem, K. G.

AU - van Oers, M. H. J.

AU - Groot, C. A. Uyl-de

AU - de Weerdtc, O.

AU - Matthssen, E.J.M.

PY - 2014

Y1 - 2014

N2 - We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received ≥1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were €41,417 (€539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy

AB - We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received ≥1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were €41,417 (€539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy

U2 - https://doi.org/10.1016/j.leukres.2013.10.029

DO - https://doi.org/10.1016/j.leukres.2013.10.029

M3 - Article

C2 - 24268350

SN - 0145-2126

VL - 38

SP - 84

EP - 90

JO - Leukemia research

JF - Leukemia research

IS - 1

ER -